JPM vs MRK
JPM: A leading global financial services firm providing comprehensive banking, investment, and asset management solutions for individuals and institutions worldwide. MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas.
Side-by-side fundamentals
| Metric | JPM | MRK | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $331.42 | $142.38 | |
| Market cap | $881.0B | $351.3B | |
| P/E as of 2026-10-08 | 13.88 | 113.71 | JPM lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.76 | n/a | |
| Net margin FY2025, SEC XBRL | +31.3% | +28.1% | JPM higher |
| ROE FY2025, SEC XBRL | +15.7% | +34.7% | MRK higher |
| ROA FY2025, SEC XBRL | +1.3% | +13.3% | MRK higher |
| Debt / equity as of 2026-09-02 | 3.30 | 1.07 | MRK lower |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +4.6% | |
| Revenue CAGR (3y) SEC XBRL | +12.3% | +3.1% | JPM higher |
| Dividend yield as of 2026-09-02 | +1.7% | +2.3% | MRK higher |
| Dividend streak (yrs) SEC XBRL | 17 | 19 | MRK higher |
| Beta as of 2026-09-02 | 0.95 | 0.30 | |
| 1-year return as of 2026-10-08 close | +9.0% | +64.8% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.